AstraZeneca Earlier Announced The Discontinuation Of The Brazikumab Inflammatory Bowel Disease Development Program
Portfolio Pulse from Charles Gross
AstraZeneca has announced the discontinuation of the brazikumab inflammatory bowel disease (IBD) development program, which included the Phase IIb/III INTREPID trial in Crohn's disease and the Phase II EXPEDITION trial in ulcerative colitis. The decision follows a review of the development timeline and the evolving competitive landscape, with no safety concerns identified.
June 01, 2023 | 9:13 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca discontinues its brazikumab IBD development program, impacting its potential future revenue from the drug.
AstraZeneca's decision to discontinue the brazikumab IBD development program will negatively impact the company's potential future revenue from the drug. The decision was made due to the development timeline and the evolving competitive landscape, which could make it harder for the drug to gain market share. This may lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100